AbbVie in its $15 billion senior notes offering in connection with its acquisition of ImmunoGen and pending acquisition of Cerevel

On February 26, 2024, AbbVie Inc. issued and sold $15.0 billion aggregate principal amount of senior unsecured notes in a registered public offering, pursuant to an underwriting agreement dated February 22, 2024.  AbbVie expects to use the net proceeds from the offering to repay $5.0 billion in term loans incurred to fund AbbVie’s recent acquisition of ImmunoGen, Inc., to fund in part AbbVie’s pending acquisition of Cerevel Therapeutics Holdings, Inc., to repay certain commercial paper borrowings, for fees and expenses in respect of the foregoing, and for general corporate purposes.  Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc., and Citigroup Global Markets Inc. acted as joint book-running managers of the offering.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to AbbVie.